Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GL0034 in Type II Diabetes Mellitus Subjects Who Are Obese or Overweight
NCT07282743Phase 2Recruiting
- Sponsor
- Sun Pharma
- Start
- Jan 2026
- Primary completion
- Apr 2027
- Modality
- Small Molecules, Modified Peptides, Native Peptides
- Countries
- 2
01
Overview
A Phase 2 trial of utreglutide in type 2 diabetes mellitus (T2DM), sponsored by Sun Pharma. Started Jan 2026; status: recruiting.
02
Drugs
utreglutide
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT07282743.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07282743.